

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/729,822	12/05/2003	Ronald Berenson	980034.422C1	8559
500 75	590 03/23/2006		EXAMINER	
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE SUITE 6300 SEATTLE, WA 98104-7092			BELYAVSKYI, MICHAIL A	
			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 03/23/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		10/729,822	BERENSON ET AL.		
		Examiner	Art Unit		
		Michail A. Belyavskyi	1644		
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	correspondence address		
WHI( - Exte after - If NO - Failt Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DONS OF THE MAILING THE	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
1)	Responsive to communication(s) filed on <u>17 M</u>	av 2004			
2a)□		action is non-final.			
3)	<b>/—</b>		secution as to the merits is		
-,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposit	ion of Claims	,			
4)⊠	Claim(s) <u>1-8,10-13,18-33,35-39,42-46,49-54 a</u>	nd 62-67 is/are pending in the an	plication		
-,—	4a) Of the above claim(s) is/are withdrawn from consideration.				
5)□					
′=					
7)	Claim(s) is/are rejected.  Claim(s) is/are objected to.				
′—	Claim(s) <u>1-8, 10-13, 18-33, 35-39, 42-46, 49-</u>	54 and 62 67 are subject to rea	triction and/or alaction		
تصرف requirem		o <del>4 and 02-07</del> are subject to res	inction and/or election		
•	on Papers				
	·				
	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.				
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).				
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.		
Priority u	ınder 35 U.S.C. § 119				
_	Acknowledgment is made of a claim for foreign  ☐ All b)☐ Some * c)☐ None of:	• • • • • • • • • • • • • • • • • • • •	-(d) or (f).		
	1. Certified copies of the priority documents				
	2. Certified copies of the priority documents have been received in Application No				
	3. Copies of the certified copies of the prior		ed in this National Stage		
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment	t(s)				
	e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)		
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ite		
	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) · No(s)/Mail Date	5) Notice of Informal Police  6) Other:	atent Application (PTO-152)		

Art Unit: 1644

## **DETAILED ACTION**

1. Applicant's amendment, filed 05/17/04 is acknowledged.

Claims 1-8, 10-13, 18-33, 35-39, 42-46, 49-54 and 62-67 are pending.

## Restriction Requirement

- 2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- I. Claims 1-4, 6-8, 10-12 and 18-24 drawn to a method for eliminating at least a substantial portion of a clonal T cell, comprising exposing a population of cells to one or more **pro-apoptotic or growth inhibiting compositions**, classified in Class 435, subclasses 372 and 372.3.
- II. Claims 5 and 13, drawn to population of T cells wherein said cells generated by the method comprising exposing a population of cells to one or more pro-apoptotic or growth inhibiting compositions, classified in Class 435, subclass 372.3.
- III. Claims 25-29,31,32, 35-38, 42-45 and 49-54 drawn to a method for eliminating at least a substantial portion of a clonal T cell, comprising exposing a population of cells to one or more compositions that sensitize at least a portion of the T cells to further activation or stimulation, classified in Class 435, subclasses 372 and 372.3.
- IV. Claims 30, 33, 39 and 46 drawn to population of T cells wherein said cells generated by the method comprising exposing a population of cells to one or more compositions that sensitize at least a portion of the T cells to further activation or stimulation, classified in Class 435, subclass 372.3.
- V. Claims 62-65, drawn to a method for activating and expanding a population of T cells by the cell surface moiety ligation, classified in Class 435, subclass 375.
- 4. Groups I, III, V are different methods. These inventions are different with respect to ingredients, method steps, and endpoints which require non-coextensive searches; therefore, each method is patentably distinct.

Application/Control Number: 10/729,822

Art Unit: 1644

5. Groups II and IV are different products. These inventions are differ with respect to their structures and physicochemical properties, which require non-coextensive searches; therefore each product is patentably distinct.

- 6. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art as shown by different classification and/or recognized divergent subject matter. Further, even though in some cases the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Moreover, a prior art search also requires a literature search. It is an undue burden for the examiner to search more than one invention. Therefore restriction for examination purposes as indicated is proper.
- 7. The examiner has required restriction between product and process claims. If applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Art Unit: 1644

- 8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 9. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840 The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MICHAIL BELYAVSKYI, PH.D. PATENT EXAMINER

3/17/06